Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04906694 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)
A Phase 2 study, sponsored by Sorrento Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
NCT04906694 is a Phase 2 study that has completed, run by Sorrento Therapeutics. The registered enrollment target is 97 participants.
The verdict
NCT04906694, a Phase 2 study, has completed, sponsored by Sorrento Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
Study Summary
This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.
Interventions
- DRUG Placebo
- BIOLOGICAL COVI-DROPS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2022-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04906694
The ClinicalTrials.gov registry entry for NCT04906694 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sorrento Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04906694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04906694 about?
NCT04906694 is a clinical study titled "Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US)". This is a double-blind study designed to investigate the efficacy, safety and PK of a single dose of COVI-DROPS or matched placebo in outpatient adults who have tested positive for COVID-19 and are either asymptomatic or have mild symptoms.
What is the current status of trial NCT04906694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2021-11-16. Estimated completion is 2022-01-13.
What interventions are being tested in trial NCT04906694?
The interventions under investigation include: Placebo (DRUG), COVI-DROPS (BIOLOGICAL).
Who is sponsoring clinical trial NCT04906694?
This trial is sponsored by Sorrento Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.